136 related articles for article (PubMed ID: 17764812)
1. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
[TBL] [Abstract][Full Text] [Related]
2. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
4. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
[TBL] [Abstract][Full Text] [Related]
5. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
[TBL] [Abstract][Full Text] [Related]
6. FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study.
Lilakos K; Viniou NA; Mavrogianni D; Vassilakopoulos TP; Dimopoulou MN; Plata E; Angelopoulou MK; Variami E; Stavrogianni N; Liapi D; Xilouri I; Galanopoulos A; Ageloudi M; Panayiotidis P; Voulgarelis M; Rombos J; Meletis J; Yataganas X; Pangalis GA
Anticancer Res; 2006; 26(2A):1201-7. PubMed ID: 16619525
[TBL] [Abstract][Full Text] [Related]
7. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
8. Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia.
Bang SM; Ahn JY; Park J; Park SH; Park J; Cho EK; Shin DB; Lee JH; Yoo SJ; Jeon IS; Kim YK; Kim HJ; Kim HN; Lee IK; Kang HJ; Shin HY; Ahn HS
J Korean Med Sci; 2008 Oct; 23(5):833-7. PubMed ID: 18955790
[TBL] [Abstract][Full Text] [Related]
9. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
[TBL] [Abstract][Full Text] [Related]
10. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia.
Kelly JC; Shahbazi N; Scheerle J; Jahn J; Suchen S; Christacos NC; Mowrey PN; Witt MH; Hostetter A; Meloni-Ehrig AM
Cancer Genet Cytogenet; 2009 Jul; 192(1):36-9. PubMed ID: 19480935
[TBL] [Abstract][Full Text] [Related]
11. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review.
Tosić N; Stojiljković M; Colović N; Colović M; Pavlović S
Cancer Genet Cytogenet; 2009 Sep; 193(2):98-103. PubMed ID: 19665070
[TBL] [Abstract][Full Text] [Related]
13. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
14. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.
Vu HA; Xinh PT; Masuda M; Motoji T; Toyoda A; Sakaki Y; Tokunaga K; Sato Y
Leukemia; 2006 Aug; 20(8):1414-21. PubMed ID: 16761019
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
16. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
17. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
Al-Tonbary Y; Mansour AK; Ghazy H; Elghannam DM; Abd-Elghaffar HA
Int J Lab Hematol; 2009 Jun; 31(3):320-6. PubMed ID: 18336585
[TBL] [Abstract][Full Text] [Related]
19. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.
Riccioni R; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Ottone T; Foà R; Testa U
Br J Haematol; 2009 Feb; 144(3):376-87. PubMed ID: 19036083
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
Razumovskaya E; Masson K; Khan R; Bengtsson S; Rönnstrand L
Exp Hematol; 2009 Aug; 37(8):979-89. PubMed ID: 19477218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
